A study of selective androgen receptor degrader (SARD) compaunds for the treatment of prostate cancer

Trial Profile

A study of selective androgen receptor degrader (SARD) compaunds for the treatment of prostate cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs Selective androgen receptor antagonists (Primary) ; Small molecules (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 15 May 2017 According to a GTx media release, the company plans to initiate this trial in first half of 2018.
    • 15 Mar 2017 According to a GTx media release, the company plans to initiate this trial in second half of 2017.
    • 31 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top